| Literature DB >> 34191091 |
Matthias Luger1, Rainer Hochgatterer2, Clemens Schopper2, Lorenz Pisecky2, Jakob Allerstorfer2, Antonio Klasan2, Tobias Gotterbarm2, Bernhard Schauer2.
Abstract
PURPOSE: Obesity is associated with increased risk for surgical complications in total hip arthroplasty (THA). The impact of obesity on short-term complication in minimally invasive (MIS) anterolateral approach is not well known. Therefore, this study was conducted to evaluate the early complications within the first 90 days after THA using a MIS anterolateral approach with a short-curved stem stratified by Body Mass Index (BMI). PATIENTS AND METHODS: A single centre consecutive series of 1052 hips in 982 patients (index surgery 2014-2019) with a short-curved stem and press fit cup implanted using a MIS anterolateral approach in supine position were screened for inclusion. Inclusion criteria were defined as end-stage primary osteoarthritis of the hip. Eventually, 878 implantations in 808 patients were included and stratified by body mass index (BMI). Peri-operative complications, within the first 90 days after surgery, were retrospectively evaluated.Entities:
Keywords: Anterolateral approach; Minimally invasive; Obesity; Short stem; Short-term complications; Total hip arthroplasty
Mesh:
Year: 2021 PMID: 34191091 PMCID: PMC8560722 DOI: 10.1007/s00264-021-05079-1
Source DB: PubMed Journal: Int Orthop ISSN: 0341-2695 Impact factor: 3.075
Patient demographics for each BMI group; bold values signal statistically significant values in testing
| Patient characteristics | Group I | Group II BMI 25 to < 30 kg/m2 | Group III BMI 30 to < 35 kg/m2 | Group IV BMI 35 to < 40 kg/m2 | Group V BMI ≥ 40 kg/m2 | P value |
|---|---|---|---|---|---|---|
| Number of hips | 242 (27.6%) | 380 (43.3%) | 169 (19.2%) | 68 (7.7%) | 19 (2.2%) | |
| Females/males | 160/82 | 181/199 | 88/81 | 39/29 | 11/8 | |
| Average age (± SD) | 68.07 (± 11.33) | 66.68 (± 9.94) | 66.94 (± 9.31) | 67.66 (± 10.54) | 65.17 (± 9.17) | 0.178 |
| ASA score | 61 ASA I 137 ASA II 44 ASA III | 82 ASA I 225 ASA II 73 ASA III | 12 ASA I 106 ASA II 49 ASA III 2 ASA IV | 3 ASA I 39 ASA II 25 ASA III 1 ASA IV | 10 ASA II 9 ASA III |
Results of discharge at home, average hospital stays, length of operation and blood loss, transfusion rate, and DINDO classification; absolute frequencies are provided for nominal and ordinal variables. Mean value as well as standard deviation (SD) is provided for metric variables. Bold values indicate significant results in post hoc testing with Bonferroni correction
| Hospital data | Group I | Group II BMI 25 to < 30 kg/m2 | Group III BMI 30 to < 35 kg/m2 | Group IV BMI 35 to < 40 kg/m2 | Group V BMI ≥ 40 kg/m2 | P value |
|---|---|---|---|---|---|---|
| Home/SNF | 176/66 | 300/80 | 130/39 | 47/21 | 15/4 | 0.266 |
| Average length of stay; d (SD) | 7.82 (± 2.18) | 8.03 (± 2.47) | 8.36 (± 3.29) | 9.82 (± 6.6) | 15.21 (± 28.04) | 0.150 |
| Average length of operation, min (± SD) | 64.16 (± 28.3) | 70.02 (± 23.97) | ||||
| Average blood loss, ml (± SD) | 271.98 (± 109.22) | 319.95 (± 124.54) | ||||
| Number of patients receiving allogenic transfusion | 13 (3.4%) | 4 (2.4%) | 2 (2.9%) | 2 (10.5%) | ||
| DINDO classification | DINDO I 2 DINDO II 6 | DINDO II 11 | DINDO II 4 DINDO IV 1 DINDO V 1 | DINDO II 2 |
List of complications within 90 days from index surgery; BMI, body mass index, kg/m2
| Complications | Total | Group I BMI ≤ 24.99 kg/m2 | Group II BMI 25 to < 30 kg/m2 | Group III BMI 30 to < 35 kg/m2 | Group IV BMI 35 to < 40 kg/m2 | Group V BMI ≥ 40 kg/m2 | P value |
|---|---|---|---|---|---|---|---|
| Surgical complication | 57 (6.5%) | 10 (4.1%) | 22 (5.8%) | 10 (7.1%) | 3 (15.8%) | ||
| Medical complication | 34 (3.9%) | 8 (3.3%) | 11 (2.69%) | 6 (3.6%) | 2 (10.5%) | ||
| Femoral nerve lesion | 3 (0.3%) | 1 (0.4%) | 1 (0.3%) | 1 (0.6%) | 0 (0.0%) | 0 (0.0%) | 0.845 |
| Fractures | 10 (1.1%) | 2 (0.2%) | 6 (0.7%) | 2 (1.2%) | 0 (0.0%) | 0 (0.0%) | 0.870 |
| Deep infection (PJI) | 12 (1.4%) | 1 (0.4%) | 4 (1.1%) | 1 (0.6%) | |||
| Hematoma | 7 (0.8%) | 0 (0.0%) | 5 (1.3%) | 1 (0.5%) | 1 (1.5%) | 0 (0.0%) | 0.318 |
| Dislocations | 9 (1.0%) | 6 (2.5%) | 2 (0.5%) | 0 (0.0%) | 1 (1.5%) | 0 (0.0%) | 0.088 |
| Wound dehiscence | 17 (1.9%) | 0 (0.0%) | 5 (1.3%) | 7 (4.1%) | 4 (5.9%) | ||
| Reoperation | 4 (0.5%) | 0 (0.0%) | 2 (0.5%) | 0 (0.0%) | 2 (2.9%) | 0 (0.0%) | 0.071 |
| Revision | 17 (1.9%) | 2 (0.8%) | 6 (1.6%) | 3 (1.8%) | 4 (5.9%) | 2 (10.5%) | |
| Readmission | 22 (2.5%) | 7 (2.9%) | 7 (1.8%) | 3 (1.8%) | 4 (5.9%) | 1 (5.3%) | 0.201 |
| Adverse events | 49 (5.6%) | 7 (2.9%) | 19 (5.0%) | 11 (6.5%) | 3 (6.1%) | ||
| Serious adverse events | 42 (4.8%) | 10 (4.1%) | 15 (3.9%) | 8 (19.0%) | 7 (16.7%) | 2 (10.5%) | 0.133 |
Bold values signal statistically significant values in testing
Results of logistic regression analysis using several dependent variables are listed per column. The estimated odds ratio as well as the corresponding confidence interval is listed per explanatory variable row-wise with additional information on the p value using a) P < 0.05, b) P < 0.01; NV, no variation (none of these patients in this category experienced these complications
| Dependent variables | Allogenic transfusion | Surgical complication | Fractures | Deep infection | Haematoma | Dislocation | Wound dehiscence | Readmission | Re-operation | Revision | Serious adverse events |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | 1.012 0.976–1.049 | 1.013 0.981–1.045 | 1.039 0.960–1.125 | 1.082 1.001–1.169 | 1.026 0.931–1.131 | 0.969 0.906–1.037 | 0.985 0.932–1.041 | 0.978 0.934–1.023 | 0.922 0.809–1.050 | 1.061 0.997–1.129 | 1.094 1.009–1.187a) |
| Sex | 0.515 0.248–1.071 | 0.489a) 0.268–0.891 | 0.298 0.061–1.441 | 1.151 0.337–3.931 | 1.632 0.343–7.768 | 0.392 0.076–2.015 | 0.288 0.090–1.041 | 0.540 0.212–1.377 | 1.142 0.123–10.617 | 0.785 0.276–2.229 | 0.571 0.286–1.141 |
| ASA | 1.178 0.664–2.091 | 0.953 0.582–1.560 | 1.583 0.507–4.940 | 0.553 0.184–1.660 | 3.461 0.870–13.764 | 0.755 0.234–2.436 | 0.667 0.263–1.691 | 1.159 0.542–2.478 | 10.476a) 1.245–88.165 | 0.842 0.345–2.053 | 1.112 0.631–1.959 |
| Surgeon’s experience | 2.683b) 1.387–5.192 | 1.119 0.601–2.081 | 1.284 0.325–5.070 | 2.675 0.801–8.930 | 1.313 0.245–7.047 | NV | 0.834 0.263–2.644 | 0.943 0.341–2.607 | 3.629 0.451–29.215 | 1.834 0.656–5.126 | 1.447 0.731–2.863 |
| BMI < 25 | Reference category | Reference category | Reference category | Reference category | NV | Reference category | NV | Reference category | NV | Reference category | Reference category |
| BMI (25 to 29.99) | 0.430a) 0.205–0.902 | 1.606 0.740–3.486 | 2.239 0.440–11.386 | 2.617 0.285–24.061 | Reference category | 0.265 0.052–1.364 | Reference category | 0.708 0.242–2.074 | Reference category | 2.031 0.400–10.309 | 1.056 0.458–2.434 |
| BMI (30 to 34.99) | 0.273a) 0.089–0.840 | 1.999 0.822–4.859 | 1.527 0.202–11.547 | 1.949 0.116–32.894 | 0.352 0.038–3.225 | NV | 3.426 1.023–11.476 | 0.619 0.153–2.502 | NV | 2.616 0.415–16.513 | 1.281 0.474–3.460 |
| BMI (35 to 39.99) | 0.324 0.071–1.477 | 4.365b) 1.674–11.382 | NV | 21.687b) 2.203–213.520 | 0.858 0.089–8.260 | 0.856 0.090–8.118 | 5.186a) 1.258–21.376 | 2.086 0.561–7.761 | 2.969 0.343–25.675 | 8.793a) 1.489–51.924 | 2.831 0.984–8.150 |
| BMI ≥ 40 | 1.400 0.280–6.989 | 4.985a) 1.188–20.921 | NV | 57.653b) 4.132–804.525 | NV | NV | 4.213 0.423–41.967 | 1.695 0.187–15.366 | NV | 20.708a) 2.430–176.446 | 3.179 0.605–16.718 |